Oxcarbazepine Suspension
Product Images NDC 51672-1393

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 51672-1393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Oxcarbazepine 01)

Chemical structure of oxcarbazepine, showing its bicyclic core and functional groups consistent with the active ingredient in the suspension form by Sun Pharmaceutical Industries, Inc.*

FDA Label Image

Figure 1 (Oxcarbazepine 02)

A Kaplan-Meier survival curve graph showing exit rates over time from day 2 to day 11 in days. It compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dashed line). The y-axis represents the exit rate, and the graph includes a log-rank test p-value of 0.0001, indicating statistical comparison between the groups.*

FDA Label Image

Figure 2 (Oxcarbazepine 03)

A Kaplan-Meier curve chart showing seizure rate over days from first dose to first seizure. The chart compares two treatment groups: Oxcarbazepine and Placebo, with seizure rate on the y-axis and days on the x-axis. A log-rank test p-value of 0.046 is noted on the graph, indicating a statistical comparison between groups.*

FDA Label Image

Figure 3 (Oxcarbazepine 04)

A Kaplan-Meier survival curve chart depicting exit rate over time in days for two treatment groups labeled 'HIGH' and 'LOW.' The solid line represents the HIGH treatment group, and the dashed line represents the LOW treatment group. A log-rank test p-value of 0.0001 is noted on the chart, indicating statistical comparison between the groups.*

FDA Label Image

Figure 4 (Oxcarbazepine 05)

A Kaplan-Meier survival curve graph showing exit rates over time (in days) for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days, ranging from 0 to 130, and the y-axis shows the exit rate from 0.0 to 1.0. The LOW group has a steeper curve indicating earlier exits compared to the HIGH group. A log-rank test with p-value=0.0001 is displayed, indicating statistical comparison of the groups.*

FDA Label Image

Principal Display Panel (250 mL Bottle Carton)

Carton packaging label for Oxcarbazepine Oral Suspension USP, 300 mg/5 mL strength. It indicates a 250 mL bottle size. The label advises shaking well before use and includes warnings for pharmacist dispensing the Medication Guide. Manufactured by Taro Pharmaceuticals, with distribution details for Taro Pharmaceuticals U.S.A., Inc. The NDC on the label is 51672-1393-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.